High prevalence of the GSTM3*A/B polymorphism in sub-Sarahan African populations

Braz J Med Biol Res, July 2010, Volume 43(7) 677-680

High prevalence of the GSTM3*A/B polymorphism in sub-Sarahan African populations

D. Teixeira^1,2, D. Vargens³, A. Príncipe^1,2, E. Oliveira^1,2, A. Amorim^1,2, M.J. Prata^1,2 and G. Suarez-Kurtz³

¹Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal

²Faculty of Sciences, University of Porto, Porto, Portugal

³Divisão de Farmacologia, Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brasil

^{Correspondence and Footnotes}

Abstract

A 3-bp insertion/deletion polymorphism in intron 6 of GSTM3 (rs1799735, GSTM3*A/*B) affects the activity of the phase 2 xenobiotic metabolizing enzyme GSTM3 and has been associated with increased cancer risk. The GSTM3*B allele is rare or absent in Southeast Asians, occurs in 5-20% of Europeans but was detected in 80% of Bantu from South Africa. The wide genetic diversity among Africans led us to investigate whether the high frequency of GSTM3*B prevailed in other sub-Saharan African populations. In 168 healthy individuals from Angola, Mozambique and the São Tomé e Príncipe islands, the GSTM3*B allele was three times more frequent (0.74-0.78) than the GSTM3*A allele (0.22-0.26), with no significant differences in allele frequency across the three groups. We combined these data with previously published results to carry out a multidimensional scaling analysis, which provided a visualization of the worldwide population affinities based on the GSTM3*A/*B polymorphism.

Key words: African populations; GSTM3 polymorphisms; Multidimensional scaling analysis; Pharmacogenetics; Population diversity

Introduction

Sistonen et al. (1,2) have recently described the worldwide patterns of distribution of functional polymorphisms in phase 1 drug-metabolizing enzymes of the cytochrome P450 (CYP) superfamily and emphasized the strong impact that population substructure may have on the variation seen in pharmacogenetic loci. The present communication extends these observations to GSTM3, a member of the glutathione S-transferase family of phase 2 enzymes, that catalyzes the conjugation of glutathione to a wide variety of xenobiotics. A 3-bp insertion/deletion polymorphism in intron 6 (rs1799735, GSTM3*A/*B) of the encoding GSTM3 gene, which may affect the regulation and ultimately the amount and activity of GSTM3 (3), provides an extreme example of inter-population differentiation. The homozygous GSTM3*B genotype is ca. 20 times more frequent in an African Bantu group (frequency 0.64) than among Europeans (frequency <0.05) (4-6). The wide genetic diversity among African populations (7) led us to investigate whether the very high frequency of the GSTM3*B allele (0.80) in South African Bantu prevails in other sub-Saharan African populations. We screened population samples from Angola, Mozambique, São Tomé e Príncipe, and combined the new data with results from the literature to carry out a multidimensional scaling analysis, which provided a visualization of the worldwide population affinities based on the GSTM3*A/B polymorphism.

Material and Methods

A sample of 168 unrelated healthy, adult men and women from Cabinda (Angola, N = 73), Mozambique (Maputo, N = 66) and São Tomé e Príncipe (N = 29) was analyzed in the present study. The samples were collected by IPATIMUP collaborators according to research protocols approved by the ethic boards of all participating institutions in Africa. A single blood sample was drawn from each subject with informed consent. Genomic DNA was extracted using standard phenol-chloroform methodologies and genotyping for the GSTM3*A/B polymorphism was performed by restriction fragment length polymorphism (RFLP) as previously described (3).

The allelic frequencies were estimated by direct gene counting. Allele and genotype frequencies were compared using the χ² test, with the level of significance set at P < 0.05. The ARLEQUIN software, version 3.0 (http://cmpg.unibe.ch/software/arlequin3) was used to test for Hardy-Weinberg equilibrium and to produce pairwise fixation index (F_ST) genetic distances between populations. Multidimensional scaling (MDS) analysis based on F_ST values was conducted by the method included in the STATISTICA data analysis software system, version 8.0. (http://www.statsoft.com).

Results and Discussion

The allele frequency and genotype distribution of the GSTM3*A/*B polymorphism in the three sub-Saharan population samples are shown in Table 1. The genotype frequencies in the three populations did not deviate from expected Hardy-Weinberg proportions. The GSTM3*B allele was three times more frequent (0.74-0.78) than the GSTM3*A allele (0.22-0.26) in each group. There were no significant differences in allele frequencies across the three populations. These results are in excellent agreement with previously published data for a Bantu group recruited at Durban, South Africa, where the frequency of GSTM3*B was 0.8 (5). Bantu people comprise the majority of the population from Mozambique and Angola, and were as well the main African contributors to the settlement of São Tomé e Príncipe in the 15th century. Thus, collectively our data indicate that the GSTM3*B variant is 3-4 times more frequent than the wild-type GSTM3*A in sub-Saharan populations of Bantu influence, spread out over a large geographical area. Within these populations, allele frequencies for the tested GSTM3 polymorphism are, however, very different from the ranges typically found either in populations of European descent, where the GSTM3*B allele usually does not add more than 20% (4-6), or in Asian populations, where the same variant is virtually absent (5). Accordingly, when F_ST distances were calculated between each of the African populations and different European or Asian populations, all values were found to be highly statistically significant (results not shown). The resulting F_ST distances were submitted to MDS analysis and the corresponding plot (Figure 1) clearly demonstrates the ability of this unique polymorphism to discriminate among populations of African, Asian or European ancestry. Not surprisingly, therefore, populations such as the Creoles from Mauritius Island, U.S. African-Americans and Brazilians self-identified as White, Intermediate or Black (8) displaying variable degrees of genetic admixture of continental ancestral populations, all occupy intermediate positions in the MDS representation. Despite the limitation of our MDS analysis, based on F_ST distances from a single gene, GSTM3, it does not seem that major distortions have been produced since the representation portraits reasonably well the known historical relationships between the populations under study.

The plot demonstrates how heterogeneous the populations referred to as African-Americans can be, as illustrated by the relative position of the two samples considered here (Af-Am1 and Af-Am2 in Figure 1). These two groups, which in fact are from U.S. states quite distant geographically - one from California, on the West Coast (9) and the other from Pennsylvania and New York, on the East Coast (10) - show very distinct levels of admixture between European and African ancestry regarding GSTM3. As a matter of fact, the demographic history varied enough among different African-American populations to explain the diverse genetic structure of contemporary African-Americans (11).

Concerning the highly heterogeneous Brazilian population, the MDS representation is consistent with our previous demonstration that the frequency of the GSTM3*B allele increases from self-reported White, to Intermediate and to Black individuals, in parallel to the increase in the average proportion of African ancestry across these groups, although at the individual level, the frequency of the GSTM3*B allele increases continuously as the individual proportion of African ancestry increases, irrespective of self-reported "color/race" (8).

The GSTM3*A/*B polymorphism has been investigated as a risk factor for cancer, with contradictory results. For example, the original observation in a North-American cohort of predominantly white individuals that the GSTM3*B/*B genotype was associated with increased risk of glioma and meningioma compared to the GSTM3*A/*A genotype (12) was not subsequently verified in residents of Sweden, England, Denmark, and Finland (13). The small number of cancer patients with the GSTM3*B/*B genotype in these studies, carried out in White populations, may account for the inconsistent association of the GSTM3*A/*B polymorphism with cancer risk. It might be anticipated that the same caveat applies to association studies of the GSTM3*A/*B polymorphism in sub-Saharan Africans, because of the very high frequency of the GSTM3*B allele. Along this reasoning, the range of GSTM3* allele frequencies among admixed groups such as Brazilians (0.32-0.64) (Ref. 8) or African-Americans (0.60-0.68) (Refs. 10,11) may prove advantageous for exploring the association of the GSTM3*A/*B polymorphism with cancer risk. This notion is consistent with suggestions that the genetic structure of admixed populations could be exploited to identify variants that underlie ethnic variation in diseases or traits of interest, in the broader context of admixture mapping (14).

Figure 1.
Multidimensional scaling (MDS) analysis plot of populations based on FST distances. In the MDS plot, distances between points approximately reproduce the original pairwise FST distances between populations. Of note, the populations of European, African and Asian descent are distinctly positioned in the upper left, lower right and lower left quadrant of the plot, respectively. Admixed populations such as Brazilians or African-Americans occupy the upper right quadrant of the plot, which is an intermediate position between African and European populations. The numbers within parentheses indicate reference number. Af-Am1 = African-American, Cau = Caucasian, Lat = Latino, As-Pa = Asian-Pacific (9); Af-Am2 = African-American (10); Cre = Creole, Aus = Australia, Chi = China, Ba = Bantu (5); Sp = Spain (15); BrW = Brazilian White, BrI = Brazilian Intermediate (self-identified as "Pardo", in Portuguese), BrB = Brazilian Black (8); Ind = Indian (16); UK = United Kingdom (17); Ge = Germany (18); Pt = Portugal (19); Fin = Finland (20); Moz = Mozambique, Ang = Angola, ST = São Tomé e Príncipe (present study).

Table 1.
Allele frequencies and observed genotype distributions of GSTM3*A/B in African populations.

References

1. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17: 93-101.

2. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009; 19: 170-179.

3. Inskip A, Elexperu-Camiruaga J, Buxton N, Dias PS, MacIntosh J, Campbell D, et al. Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1*A. Biochem J 1995; 312 (Part 3): 713-716.

4. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10: 1239-1248.

5. Tetlow N, Robinson A, Mantle T, Board P. Polymorphism of human mu class glutathione transferases. Pharmacogenetics 2004; 14: 359-368.

6. Ye Z, Song H, Higgins JP, Pharoah P, Danesh J. Five glutathione s-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: meta-analysis of 130 studies. PLoS Med 2006; 3: e91.

7. Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 2008; 9: 403-433.

8. Suarez-Kurtz G, Vargens DD, Struchiner CJ, Bastos-Rodrigues L, Pena SD. Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms. Pharmacogenet Genomics 2007; 17: 765-771.

9. Cortessis V, Siegmund K, Chen Q, Zhou N, Diep A, Frankl H, et al. A case-control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3, and risk of colorectal adenomas. Cancer Res 2001; 61: 2381-2385.

10. Park LY, Muscat JE, Kaur T, Schantz SP, Stern JC, Richie JP Jr, et al. Comparison of GSTM polymorphisms and risk for oral cancer between African-Americans and Caucasians. Pharmacogenetics 2000; 10: 123-131.

11. Reiner AP, Carlson CS, Ziv E, Iribarren C, Jaquish CE, Nickerson DA. Genetic ancestry, population sub-structure, and cardiovascular disease-related traits among African-American participants in the CARDIA Study. Hum Genet 2007; 121: 565-575.

12. De Roos AJ, Rothman N, Inskip PD, Linet MS, Shapiro WR, Selker RG, et al. Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev 2003; 12: 14-22.

13. Schwartzbaum JA, Ahlbom A, Lonn S, Malmer B, Wigertz A, Auvinen A, et al. An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev 2007; 16: 2448-2454.

14. McKeigue PM. Prospects for admixture mapping of complex traits. Am J Hum Genet 2005; 76: 1-7.

15. Ladero JM, Martinez C, Fernandez JM, Martin F, Garcia-Martin E, Ropero P, et al. Glutathione S-transferases pi 1, alpha 1 and M3 genetic polymorphisms and the risk of hepatocellular carcinoma in humans. Pharmacogenomics 2007; 8: 895-899.

16. Buch SC, Notani PN, Bhisey RA. Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis 2002; 23: 803-807.

17. Loktionov A, Watson MA, Gunter M, Stebbings WS, Speakman CT, Bingham SA. Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis 2001; 22: 1053-1060.

18. Risch A, Wikman H, Thiel S, Schmezer P, Edler L, Drings P, et al. Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas. Pharmacogenetics 2001; 11: 757-764.

19. Medeiros R, Vasconcelos A, Costa S, Pinto D, Ferreira P, Lobo F, et al. Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate 2004; 58: 414-420.

20. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, et al. Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 229-236.

Acknowledgments

Research supported by an International Cooperation Program sponsored by CAPES and Fundação para a Ciência e a Tecnologia (FCT, Portugal). FCT partially supports IPATIMUP through POCI (Programa Operacional Ciência e Inovação 2010). G. Suarez-Kurtz is supported by grants from CNPq, FAPERJ and FINEP.

Address for correspondence: G. Suarez-Kurtz, Divisão de Farmacologia, Coordenação de Pesquisa, Instituto Nacional de Câncer, 22290-290 Rio de Janeiro, RJ, Brasil. Fax: [phone]. E-mail: [e-mail]

Received March 11, 2010. Accepted May 28, 2010. Available online June 11, 2010. Published July 9, 2010.

The Brazilian Journal of Medical and Biological Research is partially financed by

Correspondence and Footnotes

Publication Dates

• Publication in this collection
  02 July 2010
• Date of issue
  July 2010

History

• Received
  11 Mar 2010
• Accepted
  28 May 2010